These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy. Mathew M; Verma RS Cancer Sci; 2009 Aug; 100(8):1359-65. PubMed ID: 19459847 [TBL] [Abstract][Full Text] [Related]
29. Immunotoxins against solid tumors. Pirker R J Cancer Res Clin Oncol; 1988; 114(4):385-93. PubMed ID: 3045130 [TBL] [Abstract][Full Text] [Related]
30. Antibodies and hematologic malignancies. Smith MR Cancer J; 2008; 14(3):184-90. PubMed ID: 18536558 [TBL] [Abstract][Full Text] [Related]
31. Bacterial Toxins for Cancer Therapy. Zahaf NI; Schmidt G Toxins (Basel); 2017 Jul; 9(8):. PubMed ID: 28788054 [TBL] [Abstract][Full Text] [Related]
32. Recombinant immunotoxins for treating cancer. FitzGerald DJ; Kreitman R; Wilson W; Squires D; Pastan I Int J Med Microbiol; 2004 Apr; 293(7-8):577-82. PubMed ID: 15149034 [TBL] [Abstract][Full Text] [Related]
33. Coupled cellular trafficking and diffusional limitations in delivery of immunotoxins to multicell tumor spheroids. Wenning LA; Murphy RM Biotechnol Bioeng; 1999 Mar; 62(5):562-75. PubMed ID: 10099565 [TBL] [Abstract][Full Text] [Related]
34. Designing immunotoxins for cancer therapy. Pennell CA; Erickson HA Immunol Res; 2002; 25(2):177-91. PubMed ID: 11999171 [TBL] [Abstract][Full Text] [Related]
35. EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells. Ochiai H; Archer GE; Herndon JE; Kuan CT; Mitchell DA; Bigner DD; Pastan IH; Sampson JH Cancer Immunol Immunother; 2008 Jan; 57(1):115-21. PubMed ID: 17634939 [TBL] [Abstract][Full Text] [Related]
36. Sequential Conditioning with Thiotepa in T Cell- Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematologic Malignancies: Comparison with Matched Related, Haplo-Mismatched, and Unrelated Donors. Duléry R; Ménard AL; Chantepie S; El-Cheikh J; François S; Delage J; Giannotti F; Ruggeri A; Brissot E; Battipaglia G; Malard F; Belhocine R; Sestili S; Vekhoff A; Delhommeau F; Reman O; Legrand O; Labopin M; Rubio MT; Mohty M Biol Blood Marrow Transplant; 2018 May; 24(5):1013-1021. PubMed ID: 29337223 [TBL] [Abstract][Full Text] [Related]
37. Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv. Stish BJ; Chen H; Shu Y; Panoskaltsis-Mortari A; Vallera DA Clin Cancer Res; 2007 May; 13(10):3058-67. PubMed ID: 17505009 [TBL] [Abstract][Full Text] [Related]
38. Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate. Newland AM; Li JX; Wasco LE; Aziz MT; Lowe DK Pharmacotherapy; 2013 Jan; 33(1):93-104. PubMed ID: 23307550 [TBL] [Abstract][Full Text] [Related]
39. Novel genetic immunotoxins and intracellular antibodies for cancer therapy. Chen SY; Marasco WA Semin Oncol; 1996 Feb; 23(1):148-53. PubMed ID: 8607024 [TBL] [Abstract][Full Text] [Related]
40. Elimination of neuroblastoma and small-cell lung cancer cells with an anti-neural cell adhesion molecule immunotoxin. Roy DC; Ouellet S; Le Houillier C; Ariniello PD; Perreault C; Lambert JM J Natl Cancer Inst; 1996 Aug; 88(16):1136-45. PubMed ID: 8757193 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]